Section 1 – Introductory Statements and Governance: Statements 1.1, 1.3, 1.5 Section 3 – Production and compounding: Statements 3.2, 3.3, 3.4 Section 5 – Patient Safety and Quality Assurance: Statements 5.1, 5.2, 5.6, 5.11
One of the major promises of mergers of multinational enterprises and of regionally assembled hospitals is the presumed economical advantage induced by scaling up and centralisation of manufacturing lines. However, new vulnerabilities are emerging in terms of quality and supply. The reliability on an undisrupted supply of medicinal products is even more in danger if hospital production is restricted because of such mergers as well. Further objectives of mergers such as reaching critical masses of patient cases and of economy of scale may critically enhance risks for patient care and patient safety.
This seminar will shed light on clinical and quality of life outcomes as compared to the financial goals of hospital mergers.
After the session, the participant should be able to:
• Assess the ratio between objectives and outcomes of hospital mergers, as well as technical approaches and workload to human resources implied; • Identify challenges to hospital pharmacies in the course of mergers; • Apply coping strategies for undesirable effects of hospital mergers; • Evaluate theoretical and real outcomes of hospital mergers in terms of clinical, financial, and patients' quality of life; and • Apply coping strategies for debugging and troubleshooting procedural shortcomings.